Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
-
Published:2023-08-25
Issue:17
Volume:24
Page:13219
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Dao Jonathan1, Conway Patrick J.23, Subramani Baskaran23ORCID, Meyyappan Devi2, Russell Sammy1, Mahadevan Daruka123
Affiliation:
1. Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX 78229, USA 2. Mays Cancer Center, University of Texas Health, San Antonio, TX 78229, USA 3. Graduate School of Biomedical Sciences, University of Texas Health San Antonio, San Antonio, TX 78229, USA
Abstract
The detection of circulating tumor DNA (ctDNA) in liquid biopsy samples as an oncological marker is being used in clinical trials at every step of clinical management. As ctDNA-based liquid biopsy kits are developed and used in clinics, companies work towards increased convenience, accuracy, and cost over solid biopsies and other oncological markers. The technology used to differentiate ctDNA and cell-free DNA (cfDNA) continues to improve with new tests and methodologies being able to detect down to mutant allele frequencies of 0.001% or 1/100,000 copies. Recognizing this development in technology, the FDA has recently given pre-market approval and breakthrough device designations to multiple companies. The purpose of this review is to look at the utility of measuring total cfDNA, techniques used to differentiate ctDNA from cfDNA, and the utility of different ctDNA-based liquid biopsy kits using relevant articles from PubMed, clinicaltrials.gov, FDA approvals, and company newsletters. Measuring total cfDNA could be a cost-effective, viable prognostic marker, but various factors do not favor it as a monitoring tool during chemotherapy. While there may be a place in the clinic for measuring total cfDNA in the future, the lack of standardization means that it is difficult to move forward with large-scale clinical validation studies currently. While the detection of ctDNA has promising standardized liquid biopsy kits from various companies with large clinical trials ongoing, their applications in screening and minimal residual disease can suffer from lower sensitivity. However, researchers are working towards solutions to these issues with innovations in technology, multi-omics, and sampling. With great promise, further research is needed before liquid biopsies can be recommended for everyday clinical management.
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference240 articles.
1. Cancer (2023, March 15). World Health Organization. Available online: https://www.who.int/news-room/fact-sheets/detail/cancer. 2. Incidence and Relative Survival by Stage at Diagnosis for Common Cancers (2023, March 15). Centers for Disease Control and Prevention. Published 10 November 2021, Available online: https://www.cdc.gov/cancer/uscs/about/data-briefs/no25-incidence-relative-survival-stage-diagnosis.htm. 3. Cost of cancer management by stage at diagnosis among Medicare beneficiaries;Reddy;Curr. Med. Res. Opin.,2022 4. The importance of identifying and validating prognostic factors in oncology;Halabi;Semin. Oncol.,2010 5. Gambardella, V., Tarazona, N., Cejalvo, J.M., Lombardi, P., Huerta, M., Roselló, S., Fleitas, T., Roda, D., and Cervantes, A. (2020). Personalized Medicine: Recent Progress in Cancer Therapy. Cancers, 12.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|